ArticleTransplantation research2013
What are the key challenges we face in kidney transplantation today?
Article in Transplantation research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Clinical Application of Machine Learning Models for Early-Stage Chronic Kidney Disease Detection.Diagnostics (Basel, Switzerland) · 2025Article
- Transitioning of renal transplant pathology from allograft to xenograft and tissue engineering pathology: Are we prepared?World journal of transplantation · 2023Review
- Reduced inflammation following human endometrial stromal/stem cell injection into male Wistar rats with cisplatin-induced acute kidney injury.BioImpacts : BI · 2022Article
- Bortezomib alleviates antibody-mediated rejection in kidney transplantation by facilitating Atg5 expression.Journal of cellular and molecular medicine · 2021Article
- Protocol Biopsies on de novo Renal-Transplants at 3 Months after Surgery: Impact on 5-Year Transplant Survival.Journal of clinical medicine · 2021Article
- Donor genetic variants in interleukin-6 and interleukin-6 receptor associate with biopsy-proven rejection following kidney transplantation.Scientific reports · 2021Article
- Perioperative blood usage and therapeutic plasma exchange in kidney transplantation during a 16-year period in South Korea.Blood transfusion = Trasfusione del sangue · 2021Article
- Curcumin Blunts IL-6 Dependent Endothelial-to-Mesenchymal Transition to Alleviate Renal Allograft Fibrosis Through Autophagy Activation.Frontiers in immunology · 2021Article
- A Single-Nucleotide Polymorphism (rs1131243) of the Transforming Growth Factor Beta Signaling Pathway Contributes to Risk of Acute Rejection in Chinese Renal Transplant Recipients.Medical science monitor : international medical journal of experimental and clinical research · 2019Article
- Bortezomib attenuates renal interstitial fibrosis in kidney transplantation via regulating the EMT induced by TNF-α-Smurf1-Akt-mTOR-P70S6K pathway.Journal of cellular and molecular medicine · 2019Article
- Enteroparasitosis infections among renal transplant recipients in Khartoum state, Sudan 2012-2013.BMC research notes · 2018Article
- Review
- Graft outcomes following immunosuppressive therapy with different combinations in kidney transplant recipients: a nationwide cohort study.Therapeutics and clinical risk management · 2018Article
- Role of endothelial-to-mesenchymal transition induced by TGF-β1 in transplant kidney interstitial fibrosis.Journal of cellular and molecular medicine · 2017Article
- Bioartificial Kidneys.Current stem cell reports · 2017Article
- Do the Benefits of Transplant Tourism Amongst Nigerian Patients Outweigh the Risks? A Single-Center Experience.International journal of organ transplantation medicine · 2017Article
- Review
- The diagnosis of posttransplantation diabetes mellitus: meeting the challenges.Current diabetes reports · 2015Review
- Sleep apnea syndrome and restless legs syndrome in kidney transplant recipients.Advanced biomedical research · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transplantation is more predictable than it was 20 to 30 years ago and innovation over the last 20 years has been rapid, delivering substantial short-term and medium-term improvements. The challenges ahead are to deliver improved results globally in the context of also preventing chronic disease and reducing the costs of treatment. Countries achieving the best rates of transplantation combine deceased and living donors and can transplant more than 50 people per annum per million population, so why can this not be achieved everywhere? The mortality rates have dropped, but they are still up to 10-fold worse than age- and sex-matched controls, such that transplantation ages individuals by 30 years in terms of mortality risk. Cardiovascular disease, infection and malignancy remain the targets if mortality is to normalize. Graft survival rates will not change until the multiple injuries constituting chronic allograft dysfunction and the problems of recurrent disease can be brought to heel. Biomarkers may provide the next innovation to advance outcomes, but early experimental tolerance protocols implemented in clinical practice in at least three centers may deliver results more quickly.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.